Le Lézard
Classified in: Health
Subject: SVY

Pulmonary Arterial Hypertension - Epidemiology Forecast to 2025


NEW YORK, Nov. 17, 2017 /PRNewswire/ -- DelveInsight's "Pulmonary Arterial Hypertension -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Pulmonary Arterial Hypertension in seven major markets (US, France, Germany, Italy, Spain, UK and Japan).

Read the full report: https://www.reportlinker.com/p05144673

It includes 10 years epidemiology historical and forecasted data of Pulmonary Arterial Hypertension. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical needs associated with the Pulmonary Arterial Hypertension. The report contains the targeted patient populations and the forecast methodology.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by DelveInsight team of industry experts.

Key Coverage and Benefits
? The Report includes the prevalent population and how will it change over the next eight years.
? Coverage of key Pulmonary Arterial Hypertension sub-populations and its prevalent or incident cases
? Prevalent or incident cases segmented by age and sex.
? The key differences in epidemiology patterns across the seven market segments.

Reasons to buy
? Developing business strategies by understanding the trends shaping and driving the global Pulmonary Arterial Hypertension market.
? Identifying prevalent patient populations as well as risk factors in the global Pulmonary Arterial Hypertension market will help to improve product design, pricing, and launch plans.
? Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension therapeutics in each of the markets covered.

Read the full report: https://www.reportlinker.com/p05144673

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

 

SOURCE Reportlinker


These press releases may also interest you

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...

at 17:15
Summary Product: Counterfeit Viagra, 100 mg sildenafil tabletsIssue: Health products - Product safety, Unauthorized productWhat to do: Immediately stop using and safely dispose of this product. Consult your health care provider if you have taken this...

at 17:00
GBLT Corp. ("GBLT" or the "Company") announces that minority shareholders have approved the voluntary delisting (the "Delisting") of the common shares of the Company from the TSX Venture Exchange ("TSXV").  Approval for the delisting was received at...



News published on and distributed by: